Spots Global Cancer Trial Database for stage iva nasal cavity and paranasal sinus squamous cell carcinoma

Every month we try and update this database with for stage iva nasal cavity and paranasal sinus squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma	NCT03422536	Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an...	Cetuximab Ficlatuzumab	18 Years -	University of Arizona
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery	NCT02538510	Head and Neck S... Recurrent Nasal... Recurrent Nasop... Recurrent Saliv... Squamous Cell C... Stage III Major... Stage III Nasal... Stage III Nasop... Stage IV Nasoph... Stage IVA Major... Stage IVA Nasal... Stage IVB Major... Stage IVB Nasal... Stage IVC Major... Stage IVC Nasal...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	University of Washington
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy	NCT01256385	Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Nasoph... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Nasal... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Nasal... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Nasal... Stage IVC Oral ... Stage IVC Oroph... Tongue Carcinom...	Cetuximab Laboratory Biom... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma	NCT03422536	Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an...	Cetuximab Ficlatuzumab	18 Years -	University of Arizona

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: